Welcome! Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Please take a moment to confirm your subscription below so we can ensure these updates reach your inbox.
Confirm Your Subscription Here
The Earnings360 Team
Just For You Why GRAIL Stock Could Be Biotech's Next Big BreakoutWritten by Bridget Bennett. Published 11/19/2025. 
Key Points - Insider buying is a reliable signal in market pullbacks, offering long-term confidence amid short-term volatility.
- Biotech stock GRAIL is one to watch, with its breakthrough cancer detection technology nearing FDA approval.
- Despite economic concerns, the American Dream is still attainable through long-term investing, saving, and strategic financial choices.
Retail investors are understandably on edge after several sessions of market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we’re still in one of the best times in history to build wealth—especially for those who think long term and follow time-tested principles. According to Green, this pullback isn’t as severe as it may feel. “Just last Wednesday, the Dow hit an all-time high,” he noted, explaining that recent selling pressure has more to do with valuation concerns and interest-rate uncertainty than any fundamental breakdown. Why the Market Pulled Back Green pins the dip to two main concerns. First, investors are increasingly questioning elevated tech and AI valuations, and earnings season is bringing those expectations into focus. Second, recent inflation data and slower hiring have dimmed hopes that the Fed will cut rates in December. With the central bank emphasizing a “data-dependent” stance, markets are less sure relief is coming this year. Why Selling Now Might Be the Wrong Move Rather than trying to predict next week’s moves, Green urges investors to zoom out. He describes himself as “a long-term optimist,” and points out that historically the market trends upward over time. Traders may want to exercise short-term caution. For long-term investors, though, these pullbacks often create opportunities to buy high-quality stocks at more attractive prices. Insider Buying Can Point the Way One reliable indicator in volatile markets is insider buying. Green notes that when officers and directors—people with access to non-public financials—are investing in their own companies, it’s worth paying attention to. He recommends tracking insider trading activity to see which stocks corporate executives are buying, not only selling. While insiders aren’t always right, their actions can be a useful signal when markets are in flux. A Biotech Breakout to Watch: GRAIL One sector Green is watching closely is biotech, where artificial intelligence is helping accelerate drug development and reduce costs. He highlighted one company in particular: GRAIL (NASDAQ: GRAL). Spun off from Illumina, GRAIL developed the Gallery Test, which can detect more than 50 types of cancer from a simple blood draw. Green has used the test himself and calls it “a good feeling” to know you’re clear of so many deadly diseases—especially cancers like pancreatic that often go undetected until late stages. With FDA fast-track status and potential insurance reimbursement on the horizon, Green views GRAIL’s $3 billion market cap as only a starting point. The Biotech Risk—and Big Pharma's Appetite Of course, biotech carries risk: most drug candidates never make it through all three phases of clinical trials. Still, larger pharmaceutical companies such as Merck (NYSE: MRK), Pfizer (NYSE: PFE), and Bristol Myers (NYSE: BMY) actively acquire promising small caps to replace expiring patents. Green pointed to Johnson & Johnson (NYSE: JNJ) as a recent example. The company invested in a private prostate cancer drug before it received FDA approval—underscoring how aggressively Big Pharma moves when clinical trials look promising. Green also notes that healthcare is relatively recession-proof. Whether the economy expands or contracts, people still seek treatment. For investors wanting to weather volatility, sectors like healthcare, utilities, consumer staples, and food companies often offer steadier demand and less drama than high-flying AI names. The American Dream Is Still Possible—But Mindset Matters Despite economic challenges, Green argues the American Dream is far from dead. He wrote The American Dream to counter the narrative that it’s out of reach, noting he was surprised by polls showing nearly 70% of Americans believe it’s no longer attainable. His point: with access to low-cost investment tools, no-commission trading, and abundant information, building wealth has never been more accessible. The challenge is knowing what to do—and having the discipline to follow through. He breaks it down simply: if a 25-year-old invests $190 per month in an S&P 500 index fund, they could have $1 million by age 65—tax-free in a Roth IRA. No extreme frugality required. “You could eat out, take trips, and still build wealth,” Green says—as long as you save consistently and let that money compound. Creative Solutions for Today’s Housing Market Housing may feel out of reach, but Green says there are options. Mortgage rates have roughly doubled and prices are up about 50% since the pandemic—but that doesn’t mean you can’t get started. He shares a personal story of buying two houses with no money down by working directly with motivated sellers and assuming their mortgages—a strategy often called a “contract for deed.” It might not get you the perfect house immediately, but it can help you begin building equity sooner. Stay Focused on the Long Game Volatile markets come and go. What matters is how you respond. Whether it’s tracking insider moves, exploring high-upside sectors like biotech, or simply believing in your ability to build a financial future, Green’s message is clear: the American Dream is still within reach. You just have to keep your eyes on it—and take the next right step.
| 
